(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Universe of Impeccable Pearls: A Manual for Valuable Gems - 2Home Plan Tips for Seniors
- 3This Overlooked Predator Is Running Out of Time—Why Conservationists Are Racing to Save the Striped Hyena
- 4Vote in favor of Your #1 Instructive Toy: Learning and Tomfoolery Joined
- 5SF Chinatown's historic Empress of China building being revived into cultural campus
- NASA is sending astronauts back to the moon. Can you see the Artemis 4 landing sites from Earth?
- Alleged Huione Group Money Laundering Boss Extradited to China
- Massive supernova explosion may have created a binary black hole
- Child influencers helped power a booming industry. It's time for a reckoning.
- Israel and Iran continue tit-for-tat attacks
- The Way to Monetary Health: Individual budget Change
- Clocks to go forward one hour in Europe as summer time starts
- Really focusing on Succulents: Tips and Procedures
- Why this Tennessee special election has the 'whole world' watching
